• Renal cell carcinoma (RCC) accounts for 3% of malignancies in adults.
  • Cigarette smoking (in more than 20% of cases) and obesity (in more than 30%) are established causal factors for RCC.
  • Four percent of cases of RCC arise from hereditary syndromes.
  • Different subtypes of RCC are characterized by distinct clinical behavior, genetic abnormalities, and molecular signatures.
  • Clear cell RCC is the most common histologic subtype, representing approximately 70% of all sporadic RCCs.
  • The von Hippel-Lindau tumor suppressor gene is genetically and epigenetically altered in more than 75% of sporadic cases of clear cell RCC.
  • Prognosis for RCC is dependent on tumor histologic type, grade, and stage.
  • Nephron-sparing surgery has become the gold standard, when feasible.
  • Follow-up guidelines for resected RCC include history, physical examination, periodic metabolic panels, and abdominal and chest computed tomography (CT) studies 4 to 6 months after surgery.
  • High-dose bolus interleukin-2 (IL-2), though toxic and of limited use in selected patients, remains a therapeutic option for clear cell RCC because of its potential for durable complete response. Additional immunotherapeutic approaches under development and promising results have been reported with the immunocheckpoint inhibitor PD-1 antibody. Identification of predictors of response to immunotherapies is undergoing.
  • Antiangiogenesis drugs have become the new standard of care in the first-line setting for clear cell RCC. Clinical benefit has also been shown with vascular endothelial growth factor and mammalian target of rapamycin inhibitors in subsequent lines of therapies. Novel targets for therapeutic interventions have been identified and are being exploited in clinical testing.
  • Optimal treatment for non–clear cell RCC remains a challenge because of the genetic differences and little knowledge of the dysregulated molecular biology driving these cancers. Rational preclinical and clinical testing is needed.

TestimonialsWhat They Are Saying

(Visited 1 times, 1 visits today)
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

Leave a Reply

Your email address will not be published. Required fields are marked *